Burns ; microbiology ; Humans ; Wound Infection ; prevention & control

Antiviral Agents ; administration & dosage ; therapeutic use ; DNA, Viral ; blood ; Hepacivirus ; genetics ; Hepatitis C, Chronic ; drug therapy ; virology ; Humans ; Interferon-alpha ; administration & dosage ; therapeutic use ; Ribavirin ; administration & dosage ; therapeutic use ; Standard of Care

Burn Units ; Cross Infection ; therapy ; Drug Resistance ; Humans ; Pneumonia ; etiology ; therapy ; Respiratory Tract Infections ; etiology ; therapy ; Ventilators, Mechanical ; adverse effects

OBJECTIVE To study the phenomenon of hepatitis B surface antigen(HBsAg) and antibody(HBsAb) both positive in blood samples.METHODS Using electro-chemo-luminescence immune system E170 to detect HBsAg and HBsAb in clinical samples and retest the both positive cases by another two reagents for HBsAg and another three reagents for HBsAb.RESULTS All 7332 samples showed 140 both HBsAg and HBsAb positive(1.9%) and 73 of them were retested for HBsAb by another three reagents which gave altogether 24 positive results,which was not related to each other.Those gave higher HBsAb value by E170 showed higher positive rate by Abbott reagent.CONCLUSIONS HBsAg and HBsAb both positive results are not rare.It may be due to the interactions between the patient and the infected hepatitis B virus.Besides,the quality of reagents and correct lab operating procedures may also affect the test results.

Fracture Fixation, Internal ; methods ; Humans ; Joint Dislocations ; surgery ; Spinal Fractures ; surgery

Animals ; Antineoplastic Agents ; therapeutic use ; Benzamides ; Dasatinib ; Drug Resistance, Neoplasm ; drug effects ; Fusion Proteins, bcr-abl ; genetics ; metabolism ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; drug therapy ; genetics ; metabolism ; Piperazines ; therapeutic use ; Protein-Tyrosine Kinases ; antagonists & inhibitors ; Pyrimidines ; pharmacology ; therapeutic use ; Thiazoles ; pharmacology ; therapeutic use

OBJECTIVE: To evaluate the stability of epirubicin hydrochloride solutions for clinical use prepared from three different formulations (one concentrated solution and two powders for injection). METHODS: Epirubicin hydrochloride in three formulations was dissolved or diluted in 0.9% sodium chloride to prepare the test solutions with concentration of 0.4mg · mL-1. These solutions were stored at different temperatures and under different shading circumstances, and samples were collected periodically during the storage to evaluate the stability, including visual inspection, pH value and content of epirubicin. RESULTS: All epirubicin solutions were stable when stored at 2-8°C under dark condition for 40 d with average content of greater than 93.76%. When stored atroom temperature with or without light exposure for 40 d, only the solution diluted from the concentrated water solution for injection was stable, as the average content remained above 92.57%. While the solutions prepared from the other two powders for injection were not stable, as the average content fell below 90% at room temperature after 2-7 d. CONCLUSION: Epirubicin solutions prepared from three different formulations are stable when stored either at 2-8°C under dark condition for 40 d or at room temperature for 24 h. The solution prepared from the concentrated water solution for injection is more stable than the solutions prepared from the two powders for injections when stored at room temperature for a long period (40 d).

The roles of chemokine and chemokine receptor family in immune diseases are drawing increasing attention, as they are very important in maintaining cell survival, inducing gene expression, directly guiding cell migration and regulating immunity. The paper reviews the expression and possible roles of chemokine receptor CXCR3 and its ligands in immune diseases, as well as the latest therapies targeting them.

Objective To investigate the changes of plasma levels of homocysteine (Hcy) and monocyte chemoattract protein 1 (MCP 1) in coronary artery disease (CAD) patients and to analyze the effect of Hcy on the expression of MCP 1. Methods The CAD diagnosis of all the studied subjects was confirmed by coronary angiography. A total of 70 patients with CAD and 50 control subjects were recruited in the study. Plasma Hcy concentration, plasma malondialdehyde (MDA) and plasma MCP 1 were determined by high performance liquid chromatography (HPLC), standard protocols and ELISA, respectively. Results Plasma levels of Hcy, MDA and MCP 1 in patients with CAD were significantly higher than those in the control subjects ( P